Gonal-F

Gonal-F is a recombinant follicle‑stimulating hormone (FSH) containing the active ingredient follitropin alfa, supplied as an injectable solution for subcutaneous administration. The product is marketed in the European Union and is available only by prescription. It is used in reproductive hormone therapy to stimulate ovarian follicular development in women and spermatogenesis in men. Strength is not specified in this summary and is formulated for precise dosing.

Gonal‑F is indicated for several reproductive conditions where stimulation of follicle‑stimulating hormone activity is required.

- Treatment of infertility caused by anovulation in women, often as part of ovulation induction protocols. - Use in assisted reproductive technology cycles, such as in vitro fertilisation (IVF) to promote multiple follicle development. - Management of hypogonadotropic hypogonadism to restore normal gonadal function in both sexes. - Treatment of male infertility associated with low sperm production due to inadequate FSH stimulation. - Adjunct therapy in controlled ovarian hyperstimulation for egg retrieval procedures.

The safety profile of Gonal‑F includes a range of observed adverse events, which are generally categorized as common (typically mild and reversible) or serious (requiring medical attention).

Common: - Injection site reactions such as redness, swelling, or mild pain. - Headache or mild dizziness. - Nausea, abdominal discomfort, or bloating. - Ovarian hyperstimulation syndrome (mild to moderate) presenting with abdominal distension and fluid retention. - Fatigue or mild weakness lasting a few days after injection. - Transient visual disturbances such as blurred vision or light sensitivity.

Serious: - Severe ovarian hyperstimulation syndrome with rapid weight gain, shortness of breath, or electrolyte imbalance. - Allergic reactions including rash, urticaria, or anaphylaxis.

When prescribing Gonal‑F, clinicians consider several precautions to minimize risks and ensure appropriate patient monitoring.

- Assess baseline ovarian reserve and hormonal profile before initiating therapy. - Monitor patients closely for signs of ovarian hyperstimulation syndrome during treatment cycles. - Use caution in patients with a history of thromboembolic disorders or severe cardiovascular disease. - Evaluate for potential allergic reactions, especially in individuals with known hypersensitivity to recombinant proteins. - Adjust dosage or discontinue therapy if severe abdominal pain, rapid weight gain, or respiratory distress occurs. - Counsel women of reproductive age to avoid pregnancy until treatment is completed and hormone levels have normalized.

Gonal‑F may interact with other medications or substances that affect hormonal balance, ovarian response, or coagulation.

Avoid: - Concomitant use of high‑dose estrogen‑containing oral contraceptives that may blunt the response to FSH. - Co‑administration with drugs that significantly increase the risk of thromboembolic events, such as hormonal replacement therapy in high‑risk patients.

Use with caution: - Gonadotropin‑releasing hormone (GnRH) agonists or antagonists used in assisted reproduction protocols; dose adjustments may be required. - Anticoagulant therapy (e.g., warfarin, direct oral anticoagulants) when there is a risk of ovarian hyperstimulation‑related fluid shifts. - Medications that affect liver metabolism (e.g., strong CYP3A4 inducers) may alter the pharmacodynamics of recombinant proteins. - Thyroid hormone replacement in patients with hypothyroidism, as thyroid status can influence ovarian response.